7 月 2 日,长春高新发布公告称,为深化公司全球化战略布局,加快公司国际化进程,增强公司在境外融资能力,进一步提升公司国际品牌形象,公司拟在境外发行股份(H 股)并在香港香港联交所上市。截图来源:企业公告长春高新主营业务包括生物制药及中成药的研发、生产和销售,辅以房地产开发等业务。经过多年的产业布局和研发投入,该公司业务板块现已覆盖基因工程、生物疫苗、抗体药物、高端化药、现代中药等多个医药细分...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.